What Xeris Biopharma Holdings (XERS)'s Profit Return and Higher 2026 Guidance Means For Shareholders
Xeris Biopharma Holdings reported a return to profitability in Q1 2026 with net income of US$2.23 million and raised its full-year 2026 revenue guidance to US$380-390 million, driven by strong momentum from its drug Recorlev. This positive update supports the company's "small portfolio" investment narrative in the near term, demonstrating its ability to cover high commercial and R&D spending. However, investors are cautioned about the concentration risk linked to its reliance on a few core therapies such as Recorlev, Gvoke, and Keveyis.
Shareholders Will Be Pleased With The Quality of Xeris Biopharma Holdings' (NASDAQ:XERS) Earnings
Xeris Biopharma Holdings' recent earnings, while not surprising in stock price reaction, showed strong underlying factors for future growth. The company reported a negative accrual ratio of -0.27, indicating its free cash flow significantly exceeded its statutory profit, with $48 million in free cash flow against $12 million in profit. However, shareholder dilution through the issuance of new shares impacted earnings per share, despite the overall positive shift from unprofitability.
Vanguard Group Inc. Buys 1,358,760 Shares of Xeris Biopharma Holdings, Inc. $XERS
Vanguard Group Inc. increased its stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 13.8% in the fourth quarter, purchasing an additional 1,358,760 shares and bringing its total holdings to over 11.18 million shares. Several other institutional investors also increased their positions in the company, with 42.75% of the stock now owned by institutions. Xeris Biopharma reported strong quarterly earnings, topping revenue estimates, and currently holds a "Hold" consensus rating from analysts with a price target of $10.80.
A Look At Xeris Biopharma Holdings (XERS) Valuation After Its Profit Turnaround And Guidance Hike
Xeris Biopharma Holdings (XERS) recently reported a profitable first quarter of 2026 and increased its full-year revenue guidance, leading to investor interest despite a year-to-date share price decline. While analysts suggest a significant undervaluation with a fair value of $11.14 per share, the company's high P/E ratio compared to industry averages signals potential valuation risks. Investors are encouraged to examine underlying data and consider both the optimistic valuation narrative and the high P/E.
Results: Xeris Biopharma Holdings, Inc. Confounded Analyst Expectations With A Surprise Profit
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) recently reported positive first-quarter results, with revenues beating expectations and a surprise statutory profit. Analysts have subsequently increased their earnings per share expectations for 2026, although revenue estimates remained stable and the consensus price target was unchanged due to the improved earnings outlook not being expected to impact long-term value creation. The company is forecast to grow substantially faster than the broader industry.
Results: Xeris Biopharma Holdings, Inc. Confounded Analyst Expectations With A Surprise Profit
Xeris Biopharma Holdings, Inc. reported strong first-quarter results, exceeding analyst expectations with revenues of US$83m and a statutory profit of US$0.01 per share. Analysts have since increased their earnings per share forecasts for 2026 to US$0.12, reflecting a more bullish sentiment, though the consensus price target remains unchanged at US$11.29. The company is projected to continue its significant revenue growth, outperforming the broader industry.
Number of shareholders of Xeris Biopharma Holdings, Inc. – DUS:2B30
This article provides details on the number of shareholders for Xeris Biopharma Holdings, Inc. trading on the Dusseldorf Stock Exchange under the ticker DUS:2B30. It presents market data and financial information related to the company, indicating the period, value, and change in shareholder numbers.
Xeris Biopharma Reports First Quarter 2026 Financial Results
Xeris Biopharma Holdings, Inc. announced strong financial results for the first quarter of 2026, with total product revenue increasing 43% year-over-year to over $82 million, primarily driven by a 95% increase in Recorlev net revenue. The company tightened its full-year 2026 revenue guidance to $380 million to $390 million, reflecting confidence in its growth trajectory and the anticipated Phase 3 initiation of XP-8121 later in the year. Xeris achieved a net income of $2.2 million for the quarter, a significant improvement from a net loss in the prior year, and reported adjusted EBITDA of $15.1 million.
Q1 2026 Xeris Biopharma Holdings Inc Earnings Call Transcript
This document contains the earnings call transcript for Xeris Biopharma Holdings Inc.'s Q1 2026 financial results. The call took place on May 7, 2026, at 12:30 PM GMT. An unidentified speaker and Allison Wei provided initial remarks, with the latter detailing the release of the company's Q1 2026 financial and operating results.
Rekorlev-driven revenue lifts Xeris Biopharma (XERS) to Q1 2026 profitability
Xeris Biopharma reported a significant turnaround in Q1 2026, achieving a net income of $2.2 million compared to a $9.2 million net loss in the prior year, primarily driven by a 38.3% increase in total revenue to $83.1 million. This growth was largely fueled by Recorlev's net product revenue nearly doubling to $49.8 million. Despite increased selling and R&D expenses, the company generated $9.9 million in operating cash flow, although it still carries significant long-term debt of $221.2 million and faces patent infringement lawsuits for Recorlev.
Xeris Biopharma Reports First Quarter 2026 Financial Results
Xeris Biopharma Holdings, Inc. announced strong financial results for the first quarter of 2026, with total product revenue increasing 43% year-over-year to over $82 million, driven primarily by a 95% surge in Recorlev net revenue. The company tightened its full-year 2026 total revenue guidance to $380 million to $390 million, reflecting confidence in continued growth and strategic execution. Xeris also reported a significant improvement in net income and Adjusted EBITDA, and plans to initiate a Phase 3 clinical trial for XP-8121 later in the year.
Xeris Biopharma (XERS) surges with 38% Q1 revenue growth and profit
Xeris Biopharma reported a strong first quarter in 2026, with total revenue increasing 38% to $83.1 million and net product revenue up 43%, primarily driven by a 95% surge in Recorlev net revenue. The company achieved a net income of $2.2 million compared to a $9.2 million loss in the prior year, and Adjusted EBITDA grew significantly. Xeris also tightened its full-year 2026 revenue guidance to $380 million to $390 million and plans to initiate a Phase 3 trial for XP-8121 later in the year.
Xeris Biopharma: Q1 Earnings Snapshot
Xeris Biopharma Holdings, Inc. (XERS) reported a first-quarter net income of $2.2 million, or 1 cent per share, surpassing Wall Street expectations. The company also exceeded revenue forecasts, posting $83.1 million against an expected $80 million, and projects full-year revenue between $380 million and $390 million.
Xeris Biopharma Holdings (Nasdaq:XERS) - Stock Analysis
This article provides a detailed stock analysis of Xeris Biopharma Holdings (Nasdaq:XERS), a commercial-stage biopharmaceutical company. It highlights that XERS is currently trading below its estimated fair value with promising future earnings growth and recent profitability. The report also covers analyst price targets, recent news, insider transactions, and financial performance data.
Xeris Biopharma’s chief legal officer sells $103,805 in stock
Xeris Biopharma's Chief Legal Officer, Beth Hecht, sold 16,667 shares of the company's common stock for $103,805 on May 1, 2026, pursuant to a Rule 10b5-1 trading plan. Despite a year-to-date decline, the stock has returned 40% over the past year and is considered slightly undervalued by InvestingPro analysis. The company recently reported strong Q4 2025 financial results, beating EPS and revenue expectations, and Barclays reiterated an Overweight rating with a $9.00 price target.
Beth Hecht Sells 16,667 Shares of Xeris Biopharma (NASDAQ:XERS) Stock
Beth Hecht, an insider at Xeris Biopharma (NASDAQ:XERS), sold 16,667 shares of the company's stock on May 1st at an average price of $6.23, reducing her stake by 1.38% to 1,193,173 shares. This transaction was part of a pre-arranged Rule 10b5-1 trading plan. The stock recently traded up 2.4% to $6.28, and analysts currently rate it a "Moderate Buy" with an average target price of $10.80.
Xeris Biopharma’s chief legal officer sells $103,805 in stock
Xeris Biopharma's Chief Legal Officer, Beth Hecht, sold 16,667 shares of the company's common stock for $103,805, executed via a Rule 10b5-1 trading plan. This transaction leaves her with 1,193,173 shares. The company recently reported strong Q4 2025 financial results, exceeding revenue and EPS expectations, and Barclays reiterated an Overweight rating with a $9.00 price target.
Xeris Biopharma (XERS) officer sells 16,667 shares under 10b5-1 plan
Xeris Biopharma Holdings officer Beth Hecht sold 16,667 shares of common stock at a weighted average price of $6.2282 per share through a pre-arranged Rule 10b5-1 trading plan. After this transaction, Ms. Hecht directly holds 1,193,173 shares. The sale, executed on May 1, 2026, had individual share prices ranging from $6.100 to $6.320.
Insider Sell Alert: Beth Hecht Sells 16,667 Shares of Xeris Biopharma Holdings Inc (XERS)
Beth Hecht, an insider at Xeris Biopharma Holdings Inc (XERS), sold 16,667 shares of the company on May 1, 2026. Following this transaction, Hecht holds 1,193,173 shares. This sale contributes to a total of 17 insider sells and 1 insider buy for XERS over the past year, and the stock is currently estimated to be significantly overvalued at $6.23 per share compared to its GF Value of $4.55.
Xeris Biopharma (XERS) to Release Earnings on Thursday
Xeris Biopharma (NASDAQ:XERS) is scheduled to release its Q1 2026 earnings before market open on Thursday, May 7th. Analysts expect an EPS of ($0.0007) and revenue of $80.675 million. The stock currently has a "Moderate Buy" consensus rating from Wall Street analysts with an average price target of $10.80.
Xeris Biopharma Reports Third Quarter 2024 Financial Results
Xeris Biopharma has released its financial results for the third quarter of 2024. The report provides key financial data for the period. Investors can track XERS and other related financial news on the Quantisnow platform.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of "Moderate Buy" from Analysts
Xeris Biopharma Holdings, Inc. (XERS) has received an average rating of "Moderate Buy" from analysts, with a 12-month target price of $10.80. Insider transactions show recent share sales by Beth Hecht and James Brady, while institutional investors have adjusted their positions. The company recently reported Q4 EPS of $0.06, beating estimates, and has a market cap of $1.03 billion.
Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) announced it will release its first quarter 2026 financial results on Thursday, May 7, 2026, before the U.S. financial markets open. Concurrently, management will host a conference call and webcast at 8:30 a.m. ET to discuss the financial and operational results. The company, known for its innovative biopharmaceutical products like Recorlev, Gvoke, and Keveyis, also has a developmental pipeline including a Phase 3-ready program for hypothyroidism.
Xeris Biopharma Holdings, Inc. ($XERS) CEO 2025 Pay Revealed
John Shannon, CEO of Xeris Biopharma Holdings, Inc. ($XERS), is estimated to have received $5,042,584 in compensation for 2025, a 24.1% increase from 2024. This information comes from a new DEF14A SEC filing. The article also details recent insider trading, institutional holdings changes, analyst ratings, and price targets for $XERS stock.
[ARS] Xeris Biopharma Holdings, Inc. SEC Filing
Xeris Biopharma Holdings, Inc. (XERS) has filed an ARS form with the SEC on April 23, 2026, at 05:09 PM UTC. The filing is available as a PDF document and contains information about the company's annual report to security holders. The company's stock overview, market cap, and recent news and SEC filings are also provided.
Xeris Biopharma (NASDAQ: XERS) details 2026 votes on pay, board, auditor
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) has scheduled its virtual 2026 Annual Meeting for June 4, 2026, where shareholders will vote on key proposals including the election of two Class II directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm for 2026, and a non-binding advisory vote on named executive officer compensation. The board recommends voting in favor of all three proposals. The company achieved strong financial results in 2025, exceeding revenue guidance and generating positive adjusted EBITDA, with significant progress in product growth and pipeline development.
Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026
Xeris Biopharma Holdings, Inc. announced it will release its first-quarter 2026 financial results on Thursday, May 7, 2026, before the U.S. financial markets open. The company will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss its financial and operational results. Interested parties can register for the call via the "Events" section of the Investor Relations website.
Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026
Xeris Biopharma Holdings, Inc. announced it will release its first quarter 2026 financial results on Thursday, May 7, 2026, before the U.S. financial markets open. The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss its financial and operational performance. Interested parties can pre-register for the call via the company's investor relations website.
Xeris Biopharma director Jeffrey Sherman to retire after 2026 annual meeting
Xeris Biopharma Holdings, Inc. announced that Dr. Jeffrey Sherman, a director, will retire and not seek re-election at the 2026 annual meeting. Dr. Sherman has served on the board since 2021 and his departure will reduce the board's size from eight to seven directors. The company clarified that his retirement is not due to any disagreements and highlighted recent strong financial results, including exceeding EPS and revenue forecasts, and a reiterated Overweight rating from Barclays with a $9.00 price target.
Xeris Biopharma Announces Board Transition as Director Retires
Xeris Biopharma Holdings, Inc. announced that director Dr. Jeffrey Sherman will retire and not seek reelection at the 2026 Annual Meeting of Stockholders, reducing the board from eight to seven members. The company clarified that his departure is not due to disagreements and signals an orderly governance transition. Analysts have a Buy rating with a $9.00 price target for XERS stock, while TipRanks' AI Analyst, Spark, rates it Neutral, citing improved financial performance tempered by weak technicals and valuation concerns.
Xeris Biopharma director Jeffrey Sherman to retire after 2026 annual meeting
Xeris Biopharma Holdings, Inc. announced that Dr. Jeffrey Sherman, a director since 2021, will retire after the company's 2026 annual meeting, leading to a reduction in the board size from eight to seven directors. His departure is not due to any disagreement with the company. This news follows strong Q4 2025 financial results for Xeris, with earnings and revenue surpassing expectations, and Barclays reiterating an Overweight rating with a $9.00 price target.
Xeris Biopharma's Jeffrey Sherman to Retire from Board
Dr. Jeffrey Sherman, a director at Xeris Biopharma, will retire and not seek re-election at the company's 2026 Annual Meeting. His term will expire at that meeting, and the board will subsequently reduce its size from eight to seven directors. This decision to retire is not due to any disagreement with the company or its management.
Director Jeffrey Sherman to retire from Xeris Biopharma (XERS) board in 2026
Dr. Jeffrey Sherman will retire from the Board of Directors of Xeris Biopharma Holdings, Inc. at the 2026 Annual Meeting of Stockholders and will not seek reelection. His departure is not due to any disagreements and will result in the board size reducing from eight to seven directors. Dr. Sherman has served on the board since 2021 and is a member of the Compensation Committee and the Nominating and Corporate Governance Committee.
Xeris Biopharma stock (US98422E1038): Is its rare disease focus strong enough to drive sustained gro
Xeris Biopharma focuses on niche therapies for endocrine and metabolic disorders, leveraging proprietary technology for ready-to-use injectable formulations. The company's core products, Gvoke for severe hypoglycemia and Recorlev for Cushing's syndrome, target underserved markets with high demand. While analysts express cautious optimism, investment risks include clinical trial setbacks, cash burn, and competitive threats, making it a speculative buy in the specialty pharma space.
Xeris Biopharma stock (US98422E1038): Is its rare disease focus strong enough to unlock new upside?
Xeris Biopharma specializes in novel delivery systems for endocrine disorders, focusing on ready-to-use formulations like Gvoke for diabetes and Recorlev for Cushing's syndrome. The company's proprietary XRifta technology and strategic focus on undervalued niches in the United States and other English-speaking markets are designed to drive growth, despite competitive pressures and pending clinical data. Investors are watching for key catalysts such as pipeline readouts and product adoption to assess its long-term value.
Xeris Biopharma stock (US98422E1038): Is its rare disease focus strong enough to unlock new upside?
Xeris Biopharma specializes in innovative therapies for rare and chronic endocrine conditions, focusing on ready-to-use formulations to simplify administration and address unmet needs in diabetes and other disorders. The company's core business model utilizes proprietary XRifta technology for stable liquid formulations, minimizing dosing errors and improving patient compliance, with revenue driven by product sales and partnerships. While lead products like Gvoke and Recorlev target significant markets, especially in the US, key risks include clinical setbacks, commercialization challenges, and market competition, requiring investors to closely monitor catalysts and financial performance.
Record Profitability, 2026 Growth Outlook and Recorlev Patent Suit Might Change The Case For Investing In Xeris Biopharma Holdings (XERS)
Xeris Biopharma (XERS) reported record profitability and revenue growth in Q4 2025, projecting over 30% growth in adjusted EBITDA and total revenue for 2026. The company also filed a patent infringement lawsuit to protect Recorlev's market exclusivity until 2040, aiming to strengthen its financial performance and competitive position. These developments, along with the recent USPTO Notice of Allowance for XP-8121, are expected to significantly influence the investment narrative and risk profile for Xeris Biopharma.
Apella Capital LLC Acquires 235,897 Shares of Xeris Biopharma Holdings, Inc. $XERS
Apella Capital LLC significantly increased its stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by acquiring an additional 235,897 shares, bringing its total ownership to 245,897 shares valued at $1.93 million. This comes as analyst sentiment for Xeris Biopharma is "Moderate Buy" with a target price of $10.80, despite recent insider selling activity. Institutional investors hold 42.75% of the stock.
XERS Financials: Revenue Breakdown, Margins & Competitor Comparison
Xeris Biopharma Holdings Inc (XERS) generates revenue primarily from its product Recorlev, which accounts for nearly half of its total sales. The company exhibits strong profitability with an 81.57% gross margin, a 9.05% operating margin, and a 0.83% net margin. When benchmarked against competitors like QURE and GERN, XERS's gross margin is competitive within the Pharmaceuticals industry.
A Look At Xeris Biopharma Holdings (XERS) Valuation After Its Q4 2025 Earnings Beat
Xeris Biopharma Holdings (XERS) reported Q4 2025 earnings of US$0.06 per share on US$85.8 million revenue, exceeding projections. Despite a recent share price decline, longer-term shareholder returns are strong, and analysts view the stock as undervalued, with a fair value of $11.14 due to anticipated growth from new product launches and proprietary technology. However, a narrow product lineup and rising R&D costs pose potential risks to future margins.
XERS.O Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for Xeris Biopharma Holdings Inc (XERS.O) as of April 8, 2026. It presents a "Strong Sell" overall technical consensus based on a combination of moving averages and oscillators. Key indicators like MACD suggest a Sell, while RSI is Neutral, and several moving averages indicate a Sell signal due to the stock trading below them.
XERS Should I Buy
This article analyzes whether to buy Xeris Biopharma Holdings Inc (XERS) stock, providing an outlook for 2026 based on analyst ratings. Wall Street analysts forecast a price increase, with Barclays initiating coverage with an Overweight rating and a $9 price target, citing improving investor sentiment in specialty pharmaceuticals. Piper Sandler maintained a Neutral rating but raised its price target to $8 from $6, noting Xeris's strong Q3 earnings and the success of its drug Recorlev.
Xeris Biopharma Holdings, Inc. (XERS) Hit a 52 Week High, Can the Run Continue?
This article discusses Xeris Biopharma Holdings, Inc. (XERS) reaching a 52-week high. It poses the question of whether the stock's upward trend will continue, indicating investor interest in its future performance.
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - April 3, 2026
Xeris Biopharma Holdings, Inc. announced on April 1, 2026, that its Compensation Committee granted restricted stock units for 304,975 shares to 90 new employees. These grants were made under Xeris' Inducement Equity Plan, exclusively for new hires as an inducement to employment, aligning with NASDAQ Listing Rule 5635(c)(4). The restricted stock units will vest over three years in equal annual installments, contingent upon continued employment.
Oppenheimer Maintains Xeris Biopharma Holdings (XERS) Outperform Recommendation
Oppenheimer has maintained its Outperform rating for Xeris Biopharma Holdings (XERS). This update indicates continued confidence from the firm in the biopharmaceutical company's performance and future prospects. Investors will likely view this as a positive signal for XERS.
XERS Technical Analysis & Stock Price Forecast
The article provides a technical analysis of Xeris Biopharma Holdings Inc (XERS), indicating a "Strong Sell" consensus based on various technical indicators and moving averages. It details specific metrics like RSI, MACD, and support/resistance levels, noting that XERS is trading below its 60-day and 200-day moving averages. The analysis suggests caution for investors considering the stock, despite some individual "buy" signals within specific moving average periods.
Q1 2025 Xeris Biopharma Holdings Inc Earnings Call Transcript
Xeris Biopharma Holdings Inc. reported a Q1 2025 revenue increase of 48%, marking its 14th consecutive quarter of over 20% product revenue growth. The company raised its revenue guidance and saw significant growth in Rekorolev, driven by strategic investments. Despite no updated peak sales guidance for Rekorolev and increased SG&A expenses, Xeris maintains a strong financial position, with positive adjusted EBITDA and FDA approval for an expanded GVO vileDX diagnostic use.
Beth Hecht Sells 16,667 Shares of Xeris Biopharma Holdings Inc (XERS)
Beth Hecht, an insider at Xeris Biopharma Holdings Inc (XERS), sold 16,667 shares on April 1, 2026, reducing her holdings to 1,209,840 shares. This transaction follows a pattern of insider selling at the company, with 16 sells and only 1 buy over the past year. The stock was trading at $5.99 on the day of sale, and with a GF Value of $4.53, it is considered significantly overvalued.
Xeris Biopharma (NASDAQ:XERS) Insider Sells $99,835.33 in Stock
Xeris Biopharma (NASDAQ:XERS) insider Beth Hecht sold 16,667 shares of the company's stock for $99,835.33 on April 1st under a pre-arranged trading plan, reducing her stake by 1.36%. This follows similar sales in February and March. The company recently reported an EPS beat but revenue slightly missed expectations, holding a "Moderate Buy" consensus rating from analysts with an average price target of $10.80.
Xeris Biopharma Approves Inducement Grants for 50,000 Shares to Two New Employees
Xeris Biopharma Holdings, Inc. has approved inducement grants for two new employees, totaling 50,000 shares of Xeris common stock. These stock options, granted on April 3, 2026, are part of the company's strategy to attract and retain talent and will vest over four years, contingent on continued service. The grants were approved by Xeris' Compensation Committee and are issued outside existing equity incentive plans, complying with NASDAQ Listing Rule 5635(c)(4).
